{"id":"02ead9de-6bce-472d-9e76-d9c954d8d603","name":"Microbot Medical","slug":"microbot-medical","description":"Microbot Medical Inc. (Nasdaq: MBOT) is a commercial-stage medical device company developing the [LIBERTY Endovascular Robotic System](/models/liberty-endovascular-robotic-system), the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The company received FDA 510(k) clearance in September 2025 and commenced limited market release in November 2025, expanding to a full market release in Q2 2026. Headquartered in Hingham, Massachusetts with R&D operations in Yokneam, Israel.","status":"public","founded":2011,"hq":"Hingham, MA, USA","hqLat":42.2417669,"hqLng":-70.8897676,"hqGeocodedAt":"2026-08-05T00:51:16.415Z","hqAddress":null,"hqPrecision":null,"website":"microbotmedical.com","fundingTotal":"92200000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://ir.microbotmedical.com/news-events/press-release","title":"Microbot Medical Wins Surgical Robotics Industry Award for the LIBERTY Endovascular Robotic System","sourceName":"GlobeNewswire"}],"keyFacts":[{"label":"FDA cleared","value":"LIBERTY Endovascular Robotic System; Nasdaq=MBOT"},{"label":"Stock","value":"Nasdaq: MBOT"},{"label":"Product","value":"LIBERTY Endovascular Robotic System"},{"label":"FDA clearance","value":"510(k) (2025)"},{"label":"Key feature","value":"Single-use, remotely operated"},{"label":"Ticker","value":"MBOT (Nasdaq)"},{"label":"Category","value":"Endovascular surgical robotics"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":"MBOT","stockExchange":"NASDAQ","secCik":"0000883975","revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-02T21:26:26.164Z","updatedAt":"2026-08-21T22:25:39.297Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/microbot-medical","url":"https://registry.deploy.report/companies/microbot-medical","name":"Microbot Medical","description":"Microbot Medical Inc. (Nasdaq: MBOT) is a commercial-stage medical device company developing the [LIBERTY Endovascular Robotic System](/models/liberty-endovascular-robotic-system), the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The company received FDA 510(k) clearance in September 2025 and commenced limited market release in November 2025, expanding to a full market release in Q2 2026. Headquartered in Hingham, Massachusetts with R&D operations in Yokneam, Israel.","identifier":"02ead9de-6bce-472d-9e76-d9c954d8d603","foundingDate":"2011","address":"Hingham, MA, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":["primary-company-ir"]}}}